Abstract:
An anchor secures an implantable device within a body by engaging a wall of the body. The anchor includes a shank and an arm extending from the shank. The shank and the arm are integrally formed from a single member. The shank attaches to the device.
Abstract:
An image forming apparatus comprises image information which outputs a sync signal and means generated image information synchronously with the sync signal; image forming means form an image on the basis of the image information at either one of a plurality of resolutions and which generates a sync request signal to request a transmission of the sync signal; and a resolution changeover means. When the image forming unit received the resolution change over request signal before the sync request signal is generated, the image forming unit executes the switching operation of the resolution, and if the image forming unit received the resolution changeover request signal after the sync request signal had been generated, the image forming unit does not execute the switching operation of the resolution.
Abstract:
Benzimidazolinone derivatives of the general formula (I): ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each is a hydrogen or halogen atom or a lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, hydroxyl, lower alkoxy, aryloxy, acyl, cyano, carboxyl, a lower alkoxycarbonyl, carbamoyl, nitro or nitrogen-containing 5- or 6-membered heterocyclic group; A is an ethylene group which may optionally have at least one branch; R.sup.4 and R.sup.5, which may be the same or different, each is a lower alkyl group or R.sup.4 and R.sup.5, together with the adjacent nitrogen atom, represent a pyrrolidinyl, piperidino or a morpholino group provided that when ##STR2## is a piperidino or diethylamino group, at least one of R.sup.1, R.sup.2 and R.sup.3 is other than a hydrogen atom, or pharmaceutically acceptable salts thereof, methods of producing the same and pharmaceutical compositions containing the same are disclosed. Pharmacologically, the above compounds (I) have pulmonary surfactant secretion promoting activity.
Abstract:
A laminar longitudinal-effect type piezoelectric or electrostrictive driver which is displaced upon application of an electric field thereto. The driver includes laminar electro-mechanical converting elements each undergoes a displacement in a direction of the electric field due to the longitudinal mode of the reverse piezoelectric effect or the electrostrictive effect, and the temperature compensating elements each of which is interposed between the appropriate adjacent two laminar electro-mechanical converting elements. The temperature compensating elements have a higher coefficient of linear thermal expansion in the direction of the electric field or direction of displacement of the driver. The driver is suitably usable for an actuator for operating a print element of a printer, for example.
Abstract:
A laminate piezoelectric actuator element comprising plural laminated piezoelectric subunits each of which comprises piezoelectric ceramic layers for generating longitudinal electrostrictive strain with a voltage, internal electrodes for applying the voltage to said piezoelectric ceramic layers, and piezoelectrically-inactive portions which correspond to parts of the piezoelectric ceramic layers having no internal electrodes laminated thereon. The piezoelectric ceramic layers and the internal electrodes are alternatively laminated on each other to form a piezoelectric subunit. An adhesive member having an attaching area equal to or smaller than an area of each internal electrode is provided between the neighboring piezoelectric subunits to thereby attach and assemble the plural piezoelectric subunits to form the piezoelectric actuator element and form slit portions between the laminated piezoelectric subunits in such a manner as to surround the adhesive member. The piezoelectric actuator element further includes external electrodes provided at both sides thereof in such a manner as to be connected to the internal electrodes to apply the voltage to the internal electrodes.
Abstract:
A novel heterocyclic bisphosphonic acid derivatives represented by the following general formula (I): ##STR1## in which .circle.Het means one of the following (A) and (B): ##STR2## wherein a dotted line in (A) means that two adjacent atoms are bonded by a single bond or a double bond, ##STR3## wherein R.sup.6 and R.sup.7 may be the same or different, each represents a hydrogen atom, a lower alkyl group, a halogen atom or a hydroxyl group,R.sup.1 represents a hydrogen atom or a hydroxyl group,R.sup.2, R.sup.3, R.sup.4 and R.sup.5 may be the same or different, each represents a hydrogen atom or a lower alkyl group,"n" is 0 or 1,provided that "n" is 1 when the ring .circle.Het means (A), and "R.sup.1 " is a hydroxyl group when the ring .dotthalfcircle.Het means (B), or pharmaceutically acceptable salts thereof and bone resorption inhibitors containing the compound as an active ingredient.
Abstract:
A novel heterocyclic bisphosphonic acid derivatives represented by the following general formula (I): ##STR1## in which, .circle.Het means one of following (A) and (B): ##STR2## wherein a dotted line in (A) means that two adjacent atoms are bonded by a single bond or a double bond, ##STR3## wherein R.sup.6 and R.sup.7 may be the same or different, each represents a hydrogen atom, a lower alkyl group, a halogen atom or a hydroxyl group,R.sup.1 represents a hydrogen atom or a hydroxyl group,R.sup.2, R.sup.3, R.sup.4 and R.sup.5 may be the same or different, each represents a hydrogen atom or a lower alkyl group,"n" is 0 or 1,provided that "n" is 1 when the ring .circle.Het means (A), and "R.sup.1 " is a hydroxyl group when the ring .circle.Het means (B),or pharmaceutically acceptable salts thereof and bone resorption inhibitors containing the compound as an active ingredient.
Abstract:
"Novel bisphosphonic acid derivatives, and a bone resorption-inhibitor and an anti-arthritis containing a bisphosphonic acid derivative represented by the formula (I): ##STR1## wherein R.sup.2 represents a hydrogen atom, an alkyl group, etc.,R.sup.2 represents a hydrogen atom or a lower alkanoyl group,R.sup.3, R.sup.4, R.sup.5 and R.sup.6 may be the same or different, each represents a hydrogen atom or lower alkyl group."
Abstract:
(Cycloalkylamino)methylenebis(phosphonic acid) represented by the general formula: ##STR1## in which, R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent a hydrogen atom or a lower alkyl group, and n represents an integer from 3 to 10, a lower alkyl ester thereof or a pharmaceutically acceptable salt thereof; and a bone-resorption inhibitor and an anti-arthritis containing the same.
Abstract:
A nuclear magnetic resonance apparatus incorporating a first trans-receiver coil, an internal lock coil, a decoupling coil, means for tuning said coils to desired frequencies, a first trans-receiving system for supplying the first trans-receiver coil with a first nuclear (such as .sup.1 H) resonance RF wave and detecting the first nuclear resonance F.I.D. signal, a second trans-receiving system for supplying the first trans-receiving coil with a second nuclear (such as .sup.13 C) resonance RF wave and detecting the second nuclear resonance F.I.D. (Free Inductance Decay) signal, a third trans-receiving system for supplying the internal lock coil with a third nuclear (such as .sup.2 D) resonance RF wave and detecting the third nuclear resonance signal, and a transmission system for supplying the first nuclear resonance RF wave to the decoupling coil, it being possible in said apparatus to observe different types of nucleus, viz; .sup.1 H and .sup.13 C without removing the internal lock by employing a third nucleus such as .sup.2 D so that the first and second nuclear spectrum can be observed at high resolution by first nuclear decoupling.